%0 Journal Article
%A Rühle, Alexander
%A Grosu, Anca-L
%A Wiedenmann, Nicole
%A Stoian, Raluca
%A Haehl, Erik
%A Zamboglou, Constantinos
%A Baltas, Dimos
%A Werner, Martin
%A Kayser, Gian
%A Nicolay, Nils
%T Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
%J Radiotherapy and oncology
%V 159
%@ 0167-8140
%C Amsterdam [u.a.]
%I Elsevier Science
%M DKFZ-2021-00704
%P 75-81
%D 2021
%Z 2021 Mar 19;159:75-81 / #EA:E055#LA:E055#
%X As both tumor hypoxia and an immunosuppressing tumor microenvironment hamper the anti-tumor activity of radiotherapy in head-and-neck squamous cell carcinoma (HNSCC), we aimed to develop an immunohistochemistry-based hypoxia-immune classifier.39 patients receiving definitive chemoradiation for HNSCC within a prospective trial were included in this analysis. Baseline tumor samples were analyzed for the hypoxia marker carbonic anhydrase IX (CAIX) and tumor-infiltrating lymphocytes (TILs) and were correlated with [18F]-misonidazole ([18F]FMISO) PET measurements. The impact of the biomarkers on the locoregional control (LRC) was examined using Cox analyses and concordance index statistics.Low CAIX (HR=0.352, 95
%K Carbonic anhydrase IX (Other)
%K FMISO PET (Other)
%K Head-and-neck squamous cell carcinoma (Other)
%K Hypoxia (Other)
%K Radiotherapy biomarker (Other)
%K Tumor-infiltrating lymphocytes (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:33753155
%R 10.1016/j.radonc.2021.03.014
%U https://inrepo02.dkfz.de/record/168136